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could emphasize. Second is the increasing
life-saving role of these devices as access
to transplants decreases. Third is the fact
that all LVADs are still subject to the same
entry criteria that were used in the 1970s
for patients with acute failure-to-wean-
from-bypass. These hemodynamic entry
criteria should be reassessed in view of the
changing medical therapy and the fact that
these implantable pumps are for patients
with chronic heart failure on transplant
waiting lists who experience worsening of
heart failure made manifest primarily by
end-organ failure and not by acute hemo-
dynamic compromise.
O. H. Frazier, MD
Director, Cardiopulmonary Transplantation
Texas Heart Institute
PO Box 20345
Houston, TX 77225-0345
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Cerebral protection with retrograde
cerebral perfusion
To the Editor:
In their article Bonser and colleagues1
claim that the cerebral flow resulting from
retrograde cerebral perfusion (RCP) is in-
sufficient to make a major contribution to
cerebral oxygenation and that the brain re-
mains ischemic. In the discussion of their
impressive work, the authors stated cor-
rectly that current data suggest that RCP
might provide only little brain perfusion in
human subjects compared with antegrade
baseline cerebral flow. Should we abandon
this adjunct to hypothermic circulatory ar-
rest, or should we explore methods to max-
imize the benefits from its application? The
effort to improve the effectiveness of RCP
during hypothermic circulatory arrest
should combine reduction of the metabolic
activity with simultaneous increase of
blood flow to fulfill the residual metabolic
requirements of the brain. In a small series
my colleagues and I2 demonstrated that the
introduction of vasodilators and anesthetics
into the retrograde perfusate tripled RCP
flow without increase in pressure and with
concomitant suppression of electric activ-
ity. In the present study it is not stated
whether brain electric activity was moni-
tored, and the individual RCP flow is not
specified. Simple pharmacologic manipula-
tions might augment RCP to 20% or 30%
of cerebral flow instead of only 10%. The
administration of potent anesthetics or
other neuroprotective agents might miti-
gate the metabolic needs of the brain. Such
maneuvers will render the brain less isch-
emic, allowing safer circulatory arrest.
Amir Elami, MD
Department of Cardiothoracic Surgery
Hadassah University Hospital
PO Box 12000
Jerusalem 91120, Israel
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Reply to the Editor:
We thank Elami for his comments concern-
ing our work on retrograde cerebral perfu-
sion (RCP).1 We acknowledged in our dis-
cussion that RCP could contribute to
metabolic support during hypothermic cir-
culatory arrest and that this contribution
could be increased by the use of vasodila-
tors. It is also possible that the use of an-
esthetics or neuroprotective agents during
RCP might afford neuroprotection. The se-
ries quoted by Elami, however, describes
only anecdotal evidence from 3 patients
undergoing differing pharmacologic inter-
ventions.2 This report described no moni-
toring of cerebral metabolism or perfusion,
therefore making inferences regarding ce-
rebral metabolic activity and blood flow
unreliable. We have previously reported
that RCP can provide some brain perfu-
sion, but we have questioned what fraction
of retrograde flow provides true brain per-
fusion.3,4 It is quite possible that increased
flow achieved by means of vasodilator ad-
ministration bypasses the brain through
venovenous and venoarterial collaterals.4
Any assumption that increasing flow in-
creases true brain perfusion and neuropro-
tection requires rigorous enquiry. We
would agree that the jury remains out on
RCP and that a beneficial clinical effect
remains to be proven. Such therapeutic in-
terventions therefore require assessment as
part of randomized controlled trials if their
efficacy is to be completely investigated.
Robert Bonser, FRCP, FRCS
Deborah Harrington, MRCS
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Angiogenesis by means of
endothelial cell transplantation
To the Editor:
In their article, “Angiogenesis by Endothe-
lial Cell Transplantation,” Kim and asso-
ciates1 present results of a novel and in-
triguing approach to angiogenic therapy.
Their preliminary report that endothelial
cell transplantation into a myocardial
scar accelerates angiogenesis suggests
a promising alternative to angiogenic
gene or protein therapy. About the same
time that their article was published, we2
presented similar results before the Amer-
ican Heart Association at our annual sci-
entific session (Anaheim, Calif) in No-
vember 2001.
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Interestingly, we created our model of
ischemic cardiomyopathy by placing an
ameroid constrictor on the branch of the
circumflex artery in 12 adult sheep.
In our experiment, 4 weeks after con-
striction, we randomly assigned 3 groups
(4 animals per group) to transpericardial
injection (3 sites per animal): sham treat-
ment (saline solution with denatured cells),
control (no injections), and endothelial cell
fibrin meshwork groups (autologous ma-
ture endothelial cells, 5  105 per injec-
tion site harvested from jugular veins).
Eight weeks after transepicardial treat-
ment, animals were assessed for myocar-
dial function (by means of echocardiog-
raphy), myocardial blood flow (MBF),
and capillary area (by means of histolo-
gy).
We demonstrated improved capillary
density and MBF in keeping with their
speculation that, “A coronary ligation
model of myocardial infarction, in which
a more extensive peri-infarct border
zone could harbor viable but hypoper-
fused cardiomyocytes and endothelial
cells, might result in greater angiogene-
sis.”
One month after constriction, MBF in
the ischemic myocardium decreased to
70% of baseline value (P  .001). Two
months after reoperation and the beginning
of treatment, animals were killed, and MBF
was found to have decreased to 28% versus
baseline values in the control and saline
solution groups (P  .001). MBF in the
endothelial cell group significantly in-
creased to 108%.
In normal nonischemic myocardium in
all 3 groups, there were 205.54  12.31
capillaries/mm2. Three months after con-
striction (and 2 months after reoperation
and beginning of treatment) in the control
and saline solution groups, there was a
decrease up to 51% in capillaries per
square millimeter (P  .001 vs baseline).
However, although this decreased signifi-
cantly in the control and saline solution
groups versus baseline values, in the endo-
thelial cell group this increased to 146%
(P  .001). Hence all of our results con-
firmed those in the report of Kim and as-
sociates.1
However, they also concluded that “in-
creasing blood flow by endothelial cell
transplantation in this model did not im-
prove contractility or prevent ventricular
dilatation,” and “we plan to perform autol-
ogous endothelial cell transplantation in
our clinically relevant porcine model of
occlusion of the left anterior descending
coronary artery. We anticipate that angio-
genesis may improve regional and global
function.”
In our investigation, 4 weeks after con-
striction, left ventricular ejection fraction
(LVEF) decreased to 75% (P .001). Two
months later, LVEF decreased to 57% in
the control and saline groups (P  .001 vs
4 weeks and baseline). In the endothelial
cell group LVEF increased to 89% of base-
line values but continued to be less than
baseline value (P  .05). However, LVEF
in this group was significantly better than
in the control and saline solution groups
(P  .001).
On the basis of our data, we think that
use of endothelial cell transplantation
within a 3-dimensional matrix system can
be used to induce angiogenesis in patients
who cannot be adequately revascularized
by using standard techniques. Exploring
autologous mature endothelial cell trans-
plantation might become a useful alterna-
tive to gene and protein therapy. We recently
completed studies involving a large number
of animals; these results are pending.
Valeri Chekanov, MD, PhDa
Nicholas Kipshidze, MD, PhDb
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Milwaukee, Wisa
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Reply to the Editor:
Chekanov and Kipshidze performed a se-
ries of experiments that appear to confirm
our findings that endothelial cell transplan-
tation improved perfusion after myocardial
injury. Recently, a variety of techniques
have been used to induce angiogenesis to
treat patients who are not candidates for
conventional methods of revascularization.
Cell transplantation has the advantage of
inducing angiogenesis by a variety of
mechanisms because the technique is not
limited to the release of a single protein.
Chekanov and Kipshidze used an endo-
thelial cell fibrin meshwork applied to the
epicardial surface of an ischemic region.
They found that this technique induced an-
giogenesis. The mode of delivery and the
number of cells engrafted might critically
affect the benefits achieved with cell trans-
plantation. The optimal conditions have not
been well defined. In addition, the cell type
that induces the most beneficial response
has not been adequately established. Endo-
thelial cells induce an extensive capillary
network, but they might not induce the
formation of sufficient conduit vessels.
Further research into this important area
might establish which cell type, which cell
number, and which mode of delivery are
optimal to induce angiogenesis.
Ren-Ke Li, MD
Richard D. Weisel, MD
Department of Cardiovascular Surgery
Toronto General Hospital
200 Elizabeth St
Toronto, Ontario M5G 2C4, Canada
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Missing data from mesothelioma
study
To the Editor:
The phase II trial of surgery and radiation
of malignant mesothelioma by Rusch and
colleagues1 is an important addition to the
literature, documenting contemporary ef-
forts to control and eventually cure this so
far incurable malignant process. The 8%
mortality after extrapleural pneumonec-
tomy reflects the tremendous strides in sur-
gical technics effected in recent decades.
The rigorous staging confirms a major at-
tempt to bring better science to this capri-
cious disease.
Nevertheless, Rusch and colleagues1
have excluded a host of important informa-
tion from their publication. I hope that they
will be able to strengthen the report by
rectifying some of these omissions:
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